Fig. 1 · Structure

Documents & Downloads

Ginkgolide B

Cat. No. A10429 CAS 15291-77-7

PAFR antagonist

Ginkgolide B (BN 52021) is a PAFR antagonist with IC50 of 3.6 μM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Ginkgolide B (BN 52021) showed functional competitive antagonism of PAF-induced aggregation in washed rabbit platelets and polymorphonuclear leukocytes. Its activity depended on the cellular response: antagonism of guinea-pig macrophage prostacyclin production required higher concentrations, and the macrophage Schild analysis did not yield a valid pA2 estimate. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PAFR 3.6 μM

Ginkgolide B Research Summary

This section summarizes 4 in vitro studies of Ginkgolide B from 3 published references. In vitro models include platelet-rich plasma from female White New Zealand rabbits.

Ginkgolide B In Vitro Studies

In guinea-pig resident peritoneal macrophages, BN 52021 shifted PAF-stimulated prostacyclin responses without significantly inhibiting the response to A23187. This control supports response-dependent antagonism within the tested assay. [1]

In human platelet-rich plasma, 10 μM BN-52021 given 5 minutes before stimulation reduced aggregation induced by alkyl-PAF or acyl-PAF. The experiment used separate agonist conditions and a separate WEB-2086 comparator. [2]

In rabbit platelet-rich plasma stimulated with 10 nM PAF, parent Ginkgolide B inhibited aggregation with an IC50 of 441.9 ± 37.9 nM (mean ± SD; three independent experiments). The tested natural-source material was reported as 91.2% pure; this is an assay-specific literature result. [3]

Competitive antagonism of PAF-induced rabbit cell aggregation

Cell-based study · Washed platelets and peripheral-blood polymorphonuclear leukocytes (PMNLs) from adult male rabbits (2–4 kg). [1]

BN 52021 shifted PAF concentration–response curves rightward without reducing their maxima. Schild analysis supported competitive antagonism in both preparations; the reported PMNL pA2 was lower than the platelet pA2.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PAF-induced washed-rabbit-platelet aggregationpA2 6.85 ± 0.18 (mean ± s.e.mean; n = 7)[1]
PAF-induced rabbit PMNL aggregationpA2 6.31 ± 0.17 (mean ± s.e.mean; n = 7)[1]

Literature-Reported Treatment Conditions

Treatment concentration
Platelets: 10^-7, 10^-6 and 10^-5 M; PMNLs: 10^-6, 10^-5 and 10^-4 M BN 52021.
Exposure duration
1 min pretreatment; aggregation followed to the maximum light-transmission response.
Method
Chronolog 540 light-transmission aggregometry at 37°C; PAF concentration–response and Schild analysis.
Vehicle
1% dimethylsulphoxide vehicle comparator.
Co-treatment
PAF stimulation; WEB 2086 and L-652,731 were separate comparator antagonists.
Reported limits
Purity/lot authentication and a fixed post-PAF observation duration were not reported in the read methods.
Methods and source locations

Compound reported in the paper: Ginkgolide B; Compound label in the paper: BN 52021

Literature BN 52021 experiments; no validation of an Adooq lot.

pp.1226–1229: aggregation Methods, Materials, Figures 1b/2b and Table 2

PAF-induced washed-rabbit-platelet aggregation: Schild analysis; slope 0.90 ± 0.06 (mean ± s.e.mean). — p.1228, Table 2; p.1227, Figure 1b; pp.1226–1228, Methods and Results

PAF-induced rabbit PMNL aggregation: Schild analysis; slope 1.01 ± 0.08 (mean ± s.e.mean). — p.1228, Table 2 and PMNL Results; p.1229, Figure 2b

Weaker antagonism in guinea-pig macrophage prostacyclin production

Cell-based study · Resident peritoneal macrophages from male guinea-pigs (400–500 g); short-term adherent-cell preparation. [1]

BN 52021 antagonized PAF-stimulated prostacyclin production at higher concentrations than needed for rabbit aggregation responses. Its Schild slope differed from unity, preventing a pA2 estimate. A23187-stimulated prostacyclin production was not significantly inhibited.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PAF-stimulated macrophage 6-oxo-PGF1α generationSchild slope 0.68 ± 0.11 (mean ± s.e.mean; n = 4); pA2 not determined[1]
6-oxo-PGF1α production with 10 μM A23187Control response No significant effect of the PAF antagonists (P > 0.05)[1]

Literature-Reported Treatment Conditions

Treatment concentration
PAF-response experiments: 10^-5, 10^-4 and 10^-3 M BN 52021; A23187 control tested the same BN 52021 concentrations.
Exposure duration
5 min antagonist equilibration at 37°C before PAF; 60 min stimulation.
Method
Radioimmunoassay of released 6-oxo-prostaglandin F1α, the prostacyclin metabolite.
Vehicle
5 μL antagonist solution in DMSO per well; control PAF responses shown in Figure 3. Final vehicle percentage is not specified for these wells in the read method.
Co-treatment
PAF concentration–response; separate 10 μM A23187 stimulation control.
Reported limits
Final DMSO percentage and compound purity/lot authentication are not specified for the adopted assay.
Methods and source locations

Compound reported in the paper: Ginkgolide B; Compound label in the paper: BN 52021

Literature BN 52021 experiments; no validation of an Adooq lot.

pp.1226–1229 macrophage Methods/Results; Figure 3b (p.1230); Tables 2–3 (pp.1228,1231)

PAF-stimulated macrophage 6-oxo-PGF1α generation: Slope differed significantly from unity (P < 0.05); PAF-response curves shifted rightward without reduction of maximal response. — p.1228, Table 2 and footnote 2; pp.1229–1230, macrophage Results and Figure 3b

6-oxo-PGF1α production with 10 μM A23187: Radioimmunoassay; Table 3 values are mean ± s.e.mean, n = 3. This control is separate from the n = 4 Schild estimate. — p.1229, final Results paragraph; p.1231, Table 3

Inhibition of PAF-induced aggregation in human platelet-rich plasma

Cell-based study · Human platelet-rich plasma from healthy volunteers; experiments repeated using at least three different donors. [2]

At 10 μM, BN-52021 reduced platelet aggregation induced by either alkyl-PAF or acyl-PAF. These are functional aggregation responses rather than direct receptor-binding measurements.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PAF-induced human platelet aggregationQualitative aggregation inhibition Reduced with BN-52021 versus the respective PAF-alone response[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM BN-52021.
Exposure duration
5 min pretreatment; aggregation recorded for up to 6 min.
Method
Chrono-log platelet aggregometry at 37°C.
Vehicle
DMSO stock diluted with saline; final DMSO did not exceed 0.1%.
Co-treatment
Separate stimulation with 8 μM alkyl-PAF or 800 μM acyl-PAF. WEB-2086 (10 μM) was a separate comparator, not a combination treatment.
Reported limits
BN-52021 purity and lot analysis are not provided in the read methods; no exact inhibition percentage is extracted from the plot.
Methods and source locations

Compound reported in the paper: Ginkgolide B; Compound label in the paper: BN-52021

Functional effects of literature BN-52021 in human PRP.

Human platelet aggregation and Statistics methods; platelet Results; Figure 4C,D,G and caption

PAF-induced human platelet aggregation: Figure 4 traces and bar graph inspected; no curve-derived decimals. Each set used one donor and was repeated with at least three donors. — Figure 4C,D,G (actual plotted agonist labels); Human platelet aggregation and Statistics; Results: PAF homologues induce platelet aggregation

Parent Ginkgolide B potency in rabbit platelet-rich plasma

Cell-based study · Platelet-rich plasma from female White New Zealand rabbits (3–4 kg). [3]

Natural-source parent Ginkgolide B (compound 1; reported purity 91.2%) inhibited PAF-induced aggregation. The measured parent-compound IC50 is kept separate from more potent amide derivative 2.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of PAF-induced rabbit PRP aggregationIC50 441.9 ± 37.9 nM[3]

Literature-Reported Treatment Conditions

Treatment concentration
Parent-compound series shown in Figure 3: 50, 100, 200, 400 and 800 nM.
Exposure duration
Maximum aggregation response within 5 min after PAF; preincubation duration not specified in Section 4.3.2.
Method
AggRAM light-transmission aggregometry at 37°C; nonlinear regression for IC50.
Vehicle
Solvent comparator; Figure 3 labels the control as 0.5% DMSO.
Co-treatment
10 nM PAF stimulation. Amide derivatives were separate comparators.
Reported limits
Parent pretreatment duration, final solvent percentage for each parent concentration and impurity identities are not specified in the read assay methods.
Methods and source locations

Compound reported in the paper: Ginkgolide B; Compound label in the paper: GB (1)

Assay-specific result for the reported 91.2%-pure parent material; not a lot-independent potency specification.

Sections 4.1, 4.3.1–4.3.2; Table 3; Figure 3 left panel/caption

Inhibition of PAF-induced rabbit PRP aggregation: Table 3 and Figure 3; mean ± S.D. of three independent experiments (Figure 3 caption); PAF 10 nM in Section 4.3.2. — Table 3, GB (1) row; Figure 3 left panel and caption; Sections 4.1 and 4.3.1–4.3.2

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 15291-77-7
Applications PAFR antagonist
Formula C20H24O10
Molecular Weight 424.4
Synonyms BN 52021
SMILES
CC1C(=O)OC2C1(C34C(=O)OC5C3(C2O)C6(C(C5)C(C)(C)C)C(C(=O)OC6O4)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 84 mg/mL (197.92 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
30% propylene glycol, 5% Tween 80, 65% D5W

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ginkgolide B Research References

  1. [1] A G Stewart, G J Dusting. Characterization of receptors for platelet-activating factor on platelets, polymorphonuclear leukocytes and macrophages British journal of pharmacology (1988). PMID: 2850058 DOI: 10.1111/j.1476-5381.1988.tb11642.x Source material
  2. [2] Vyala Hanumanthareddy Chaithra, Shancy Petsel Jacob, Chikkamenahalli Lakshminarayana Lakshmikanth, et al. Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAF Journal of lipid research (2018). PMID: 30139761 DOI: 10.1194/jlr.m085704 Source material
  3. [3] Qiang Shang, Xiaobo Zhou, Ming-Rong Yang, et al. Amide Derivatives of Ginkgolide B and Their Inhibitory Effects on PAF-Induced Platelet Aggregation ACS omega (2021). PMID: 34514222 DOI: 10.1021/acsomega.1c01682 Source material

Added to your cart

View Cart Checkout
Loading...